Division of AstraZeneca PLC
Latest From AstraZeneca AB
High court denies petition by Mylan to limit patent litigation venue and petition by Merck KGAA to address whether “on sale” bar to obtaining patent applies to non-public sales; Zarxio case to go to conference Friday.
Federal Circuit decision permits brand-name drug makers to file infringement suits against generic manufacturers in whatever jurisdiction they wish.
Federal Circuit denies Mylan's bid to dismiss litigation in Delaware; PhRMA, BIO and Teva argued that brand manufacturers should be allowed to sue multiple generic manufacturers in a single forum.
AstraZeneca wins a temporary restraining order preventing Dr. Reddy’s from marketing an all-purple generic of the proton pump inhibitor Nexium. OTC switch application consultant Susan Lavine Coleman says the decision “sends a strong warning to future OTC private label manufacturers”
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- AstraZeneca PLC
- Senior Management
- Contact Info
Phone: 8 553 260 00
Södertälje, SE-151 85
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.